April 27, 2010 (FinancialWire) — PPD, Inc. (NASDAQ: PPDI) said it has opened a vaccine clinical research center in Taizhou, China to strengthen its clinical research and development services in one of the country’s major regions for conducting vaccine studies.

Through the center, PPD said will provide clinical monitoring services to global and local biopharmaceutical companies seeking to develop vaccines in China.

Located at the Taizhou China Medical City, the center is meant to help biopharmaceutical companies address unique requirements for conducting vaccine clinical trials in the country.

Vaccine studies in China are conducted by the Chinese Center for Disease Control and Prevention instead of at Phase I clinics or by investigators at hospitals, and they require thousands of patients for enrollment, compared to hundreds for studies conducted in other countries. Yet, according to PPD, China has a short recruitment period for vaccine trials.

North Carolina-based PPD is a global contract research organization providing drug discovery, development and lifecycle management services. Its clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations.

The firm has offices in 41 countries and more than 10,500 professionals worldwide.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [bsnnssb] [exxpndgbsns] [ntrntnlcmpnsbsnss]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.